Cancer spending to reach $200B by 2020
Cancer care may cost the U.S. two-thirds more in the next decade, potentially topping $200 billion by 2020 as the population ages and drug prices continue to rise. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What’s your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- New York Genome Center Announces Formal Commencement of Collaborative Relationship with Illumina
- Baxano Completes Enrollment in Lumbar Spinal Stenosis Study
- PRA Expands Operations in Europe
- New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
- Greatbatch to Establish New Global Headquarters
- More Press Releases
Featured Jobs
-
Sr. Director/Executive Director of Operations, Inflammation and Immunology CRD Job
Celgene Corporation - Tokyo, Ja, US -
Senior Manager, API Development
TESARO - Waltham, MA -
Microbiology Scientist
C3 Jian - Marina Del Rey, CA -
Pharmacist (Drug Safety and Product Information) Job
Yoh - Durham, NC, USA -
Project Manager, Marketing Excellence Job
Celgene Corporation - Summit, NJ, US
Comments